Island Pharmaceuticals Expands Trials Amid New Funding
Company Announcements

Island Pharmaceuticals Expands Trials Amid New Funding

Island Pharmaceuticals Ltd (AU:ILA) has released an update.

Island Pharmaceuticals Ltd is making notable strides in antiviral drug development, securing a new funding of A$3.5 million to bolster its clinical trials and pipeline expansion. The company has initiated a Phase 2a/b PROTECT clinical trial and is exploring the acquisition of an antiviral molecule from BioCryst. With a new non-executive director on board, Island aims to leverage fresh insights and robust financial backing to drive future growth.

For further insights into AU:ILA stock, check out TipRanks’ Stock Analysis page.

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App